Identification of coagulation-associated subtypes of lung adenocarcinoma and establishment of prognostic models

Mengyang Han; Xiaoli Wang; Yaqi Li; Jianjun Tan; Chunhua Li; Wang Sheng; Mengyang Han; Xiaoli Wang; Yaqi Li; Jianjun Tan; Chunhua Li; Wang Sheng

doi:10.3934/mbe.2023470

Mathematical Biosciences and Engineering

2023, Volume 20, Issue 6: 10626-10658. doi: 10.3934/mbe.2023470

Previous Article Next Article

Research article

Identification of coagulation-associated subtypes of lung adenocarcinoma and establishment of prognostic models

1.
Department of Pharmacology, Beijing International Science and Technology Cooperation Base of Antivirus Drug, Faculty of Environment and Life, Beijing University of Technology, Beijing 100124, China
2.
Department of Biomedical Engineering, Faculty of Environment and Life, Beijing University of Technology, Beijing 100124, China

Received: 31 January 2023 Revised: 15 March 2023 Accepted: 24 March 2023 Published: 13 April 2023

Lung adenocarcinoma (LUAD), the most common subtype of lung cancer, is a global health challenge with high recurrence and mortality rates. The coagulation cascade plays an essential role in tumor disease progression and leads to death in LUAD. We differentiated two coagulation-related subtypes in LUAD patients in this study based on coagulation pathways collected from the KEGG database. We then demonstrated significant differences between the two coagulation-associated subtypes regarding immune characteristics and prognostic stratification. For risk stratification and prognostic prediction, we developed a coagulation-related risk score prognostic model in the Cancer Genome Atlas (TCGA) cohort. The GEO cohort also validated the predictive value of the coagulation-related risk score in terms of prognosis and immunotherapy. Based on these results, we identified coagulation-related prognostic factors in LUAD, which may serve as a robust prognostic biomarker for therapeutic and immunotherapeutic efficacy. It may contribute to clinical decision-making in patients with LUAD.
- lung adenocarcinoma,
- coagulation,
- unsupervised clustering,
- risk score,
- immunotherapy,
- cascade
Citation: Mengyang Han, Xiaoli Wang, Yaqi Li, Jianjun Tan, Chunhua Li, Wang Sheng. Identification of coagulation-associated subtypes of lung adenocarcinoma and establishment of prognostic models[J]. Mathematical Biosciences and Engineering, 2023, 20(6): 10626-10658. doi: 10.3934/mbe.2023470

Related Papers:

Abstract

Lung adenocarcinoma (LUAD), the most common subtype of lung cancer, is a global health challenge with high recurrence and mortality rates. The coagulation cascade plays an essential role in tumor disease progression and leads to death in LUAD. We differentiated two coagulation-related subtypes in LUAD patients in this study based on coagulation pathways collected from the KEGG database. We then demonstrated significant differences between the two coagulation-associated subtypes regarding immune characteristics and prognostic stratification. For risk stratification and prognostic prediction, we developed a coagulation-related risk score prognostic model in the Cancer Genome Atlas (TCGA) cohort. The GEO cohort also validated the predictive value of the coagulation-related risk score in terms of prognosis and immunotherapy. Based on these results, we identified coagulation-related prognostic factors in LUAD, which may serve as a robust prognostic biomarker for therapeutic and immunotherapeutic efficacy. It may contribute to clinical decision-making in patients with LUAD.

References

[1]	F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68 (2018), 394–424. https://doi.org/10.3322/caac.21492 doi: 10.3322/caac.21492
[2]	W. Chen, R. Zheng, P. D. Baade, S. Zhang, H. Zeng, F. Bray, et al., Cancer statistics in China, 2015, CA Cancer J. Clin., 66 (2016), 115–132. https://doi.org/10.3322/caac.21338 doi: 10.3322/caac.21338
[3]	D. Yang, Y. Liu, C. Bai, X. Wang, C. A. Powell, Epidemiology of lung cancer and lung cancer screening programs in China and the United States, Cancer Lett., 468 (2020), 82–87. https://doi.org/10.1016/j.canlet.2019.10.009 doi: 10.1016/j.canlet.2019.10.009
[4]	R. Ruiz-Cordero, W. P. Devine, Targeted therapy and checkpoint immunotherapy in lung cancer, Surg. Pathol. Clin., 13 (2020), 17–33. https://doi.org/10.1016/j.path.2019.11.002 doi: 10.1016/j.path.2019.11.002
[5]	J. Vansteenkiste, L. Crinò, C. Dooms, J. Y. Douillard, C. Faivre-Finn, E. Lim, et al., 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 25 (2014), 1462–1474. https://doi.org/10.1093/annonc/mdu089 doi: 10.1093/annonc/mdu089
[6]	F. R. Hirsch, P. A. Bunn Jr, Adjuvant TKIs in NSCLC: what can we learn from RADIANT, Nat. Rev. Clin. Oncol., 12 (2015), 689–690. https://doi.org/10.1038/nrclinonc.2015.202 doi: 10.1038/nrclinonc.2015.202
[7]	S. Sampath, Treatment: Radiation therapy, in Lung Cancer, Springer, 170 (2016), 105–118. https://doi.org/10.1007/978-3-319-40389-2_5
[8]	M. Ahn, J. M. Sun, S. H. Lee, J. S. Ahn, K. Park, EGFR TKI combination with immunotherapy in non-small cell lung cancer, Expert Opin. Drug Saf., 16 (2017), 465–469. https://doi.org/10.1080/14740338.2017.1300656 doi: 10.1080/14740338.2017.1300656
[9]	J. F. Gainor, A. M. Varghese, S. H. Ignatius Ou, S. Kabraji, M. M. Awad, R. Katayama, et al., ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer, Clin. Cancer Res., 19 (2013), 4273–4281. https://doi.org/10.1158/1078-0432.CCR-13-0318 doi: 10.1158/1078-0432.CCR-13-0318
[10]	Z. Wang, K. S. Embaye, Q. Yang, L. Qin, C. Zhang, L. Liu, et al., Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism-related genes, Cancer Cell Int., 21 (2021). https://doi.org/10.1186/s12935-021-01915-x doi: 10.1186/s12935-021-01915-x
[11]	P. E. Serrano, S. Parpia, L. A. Linkins, L. Elit, M. Simunovic, L. Ruo, et al., Venous thromboembolic events following major pelvic and abdominal surgeries for cancer: A prospective cohort study, Ann. Surg. Oncol., 25 (2018), 3214–3221. https://doi.org/10.1245/s10434-018-6671-7 doi: 10.1245/s10434-018-6671-7
[12]	A. Falanga, M. Marchetti, L. Russo, The mechanisms of cancer-associated thrombosis, Thromb. Res., 135 (2015), 8–11. https://doi.org/10.1016/S0049-3848(15)50432-5 doi: 10.1016/S0049-3848(15)50432-5
[13]	L. Bao, S. Zhang, X. Gong, G. Cui, Trousseau syndrome related cerebral infarction: Clinical manifestations, laboratory findings and radiological features, J. Stroke Cerebrovasc. Dis., 29 (2020), 104891. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104891 doi: 10.1016/j.jstrokecerebrovasdis.2020.104891
[14]	Y. Li, S. Wei, J. Wang, L. Hong, L. Cui, C. Wang, Analysis of the factors associated with abnormal coagulation and prognosis in patients with non-small cell lung cancer (in Chinese), Zhongguo fei ai za zhi, 17 (2014), 789–796. https://doi.org/10.3779/j.issn.1009-3419.2014.11.04 doi: 10.3779/j.issn.1009-3419.2014.11.04
[15]	M. J. Goldman, M. J. Craft, M. Hastie, K. Repečka, F. McDade, A. Kamath, et al., Visualizing and interpreting cancer genomics data via the Xena platform, Nat. Biotechnol., 38 (2020), 675–678. https://doi.org/10.1038/s41587-020-0546-8 doi: 10.1038/s41587-020-0546-8
[16]	Q. He, J. Yang, Y. Jin, Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma, Briefings Bioinf., 23 (2022). https://doi.org/10.1093/bib/bbac291 doi: 10.1093/bib/bbac291
[17]	C. Ren, J. Li, Y. Zhou, S. Zhang, Q. Wang, Typical tumor immune microenvironment status determine prognosis in lung adenocarcinoma, Transl. Oncol., 18 (2022), 101367. https://doi.org/10.1016/j.tranon.2022.101367 doi: 10.1016/j.tranon.2022.101367
[18]	A. Mayakonda, D. C. Lin, Y. Assenov, C. Plass, H. P. Koeffler, Maftools: efficient and comprehensive analysis of somatic variants in cancer, Genome Res., 28 (2018), 1747–1756. https://doi.org/10.1101/gr.239244.118 doi: 10.1101/gr.239244.118
[19]	Y. Zhou, T. O. Sharpee, Using global t-SNE to preserve intercluster data structure, Neural Comput., 34 (2022), 1637–1651. https://doi.org/10.1162/neco_a_01504 doi: 10.1162/neco_a_01504
[20]	M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., 15 (2014), 550. https://doi.org/10.1186/s13059-014-0550-8 doi: 10.1186/s13059-014-0550-8
[21]	The Gene Ontology Consortium, Gene Ontology Consortium: going forward, Nucleic Acids Res., 43 (2015), 1049–1056. https://doi.org/10.1093/nar/gku1179 doi: 10.1093/nar/gku1179
[22]	G. Yu, L. G. Wang, Y. Han, Q. Y. He, clusterProfiler: an R package for comparing biological themes among gene clusters, OMICS: J. Integr. Biol., 16 (2012), 284–287. https://doi.org/10.1089/omi.2011.0118 doi: 10.1089/omi.2011.0118
[23]	J. Friedman, T. Hastie, R. Tibshirani, Regularization paths for generalized linear models via coordinate descent, J. Stat. Software, 33 (2010), 1–22.
[24]	P. J. Heagerty, T. Lumley, M. S. Pepe, Time-dependent ROC curves for censored survival data and a diagnostic marker, Biometrics, 56 (2000), 337–344. https://doi.org/10.1111/j.0006-341x.2000.00337.x doi: 10.1111/j.0006-341x.2000.00337.x
[25]	Z. Gu, R. Eils, M. Schlesner, Complex heatmaps reveal patterns and correlations in multidimensional genomic data, Bioinformatics, 32 (2016), 2847–2849. https://doi.org/10.1093/bioinformatics/btw313 doi: 10.1093/bioinformatics/btw313
[26]	B. Chen, M. S. Khodadoust, C. L. Liu, A. M. Newman, A. A. Alizadeh, Profiling tumor infiltrating immune cells with CIBERSORT, in Cancer Systems Biology, Springer Nature, 1711 (2018), 243–259. https://doi.org/10.1007/978-1-4939-7493-1_12
[27]	H. T. Sørensen, L. Mellemkjaer, J. H. Olsen, J. A. Baron, Prognosis of cancers associated with venous thromboembolism, N. Engl. J. Med., 343 (2000), 1846–1850. https://doi.org/10.1056/NEJM200012213432504 doi: 10.1056/NEJM200012213432504
[28]	Y. B. Yu, J. P. Gau, C. Y. Liu, M. Yang, S. Chiang, H. Hsu, et al., A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system, Thromb. Haemostasis, 108 (2012), 225–235. https://doi.org/10.1160/TH12-01-0010 doi: 10.1160/TH12-01-0010
[29]	N. S. Kwon, K. J. Baek, D. S. Kim, H. Y. Yun, Leucine-rich glioma inactivated 3: Integrative analyses reveal its potential prognostic role in cancer, Mol. Med. Rep., 17 (2018), 3993–4002. https://doi.org/10.3892/mmr.2017.8279 doi: 10.3892/mmr.2017.8279
[30]	A. P. Wolffe, Architectural transcription factors, Science, 264 (1994), 1100–1101. https://doi.org/10.1126/science.8178167 doi: 10.1126/science.8178167
[31]	Z. Shang, X. Niu, K. Zhang, Z. Qiao, S. Liu, X. Jiang, et al., FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma, J. Mol. Med., 97 (2019), 1657–1668. https://doi.org/10.1007/s00109-019-01848-z doi: 10.1007/s00109-019-01848-z
[32]	M. Majesky, Vascular development, Arterioscler. Thromb. Vasc. Biol., 38 (2018), 17–24. https://doi.org/10.1161/ATVBAHA.118.310223 doi: 10.1161/ATVBAHA.118.310223

Reader Comments

Your name:*

Email:*
© 2023 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)